Now Available: The Orphan Drug Market Outlook to 2017
Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, with orphan drugs seen as a great opportunity for this. Our report provides analysis of this sector and includes brands that have gained orphan drug approval from the FDA, as well as Phase III pipeline candidates that have gained orphan drug designation from the FDA.
View full press release